Abstract
Platelet Amyloid Precursor Protein ratio of different abnormal forms and 99mTc–ECD SPECT perfusion analysis were evaluated in Mild Cognitive Impairment (MCI) subjects who progressed to Alzheimer Disease (AD) and in stable MCI. We report that their combined evaluation increases the discriminative power of the analysis in identifying presymptomatic AD. The positive predictive value of these combined markers in identifying progressive MCI was 0.87, and the negative predictive value was 0.90. This observation suggests that the interplay of different markers should be considered for enhancing diagnostic accuracy of pre–clinical AD.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E (1999) Mild cognitive impairment. Clinical characterization and outcome. Arch Neurol 56:303–308
Luis CA, Loewenstein DA, Acevedo A, Barker WW, Duara R (2003) Mild cognitive impairment: Directions for future research. Neurology 61:438–444
Buerger K, Teipel SJ, Zinkowski R, et al. (2002) CSF tau protein phosphorilated at threonine 231 correlates with cognitive decline in MCI subjects. Neurology 59:627–629
Riemenschneider M, Lautenschlager N, Wagenpfeil S, Diehl J, Drzezga A, Kurz A (2002) Cerebrospinal fluid tau and β–amyloid 42 proteins identify Alzheimer disease in subjects with Mild Cognitive Impairment. Arch Neurol 59:1729–1734
Johnson KA, Jones K, Holman BL, Becker JA, Spiers PA, Satlin A, Albert MS (1998) Preclinical prediction of Alzheimer's disease using SPECT. Neurology 50:1563–1571
Borroni B, Colciaghi F, Caltagirone C, Rozzini L, Broglio L, Cattabeni F, Di Luca M, Padovani A (2003) Platelet Amyloid Precursor Protein Abnormalities in mild cognitive impairment predict conversion to dementia of Alzheimer type: a 2–year follow–up study. Arch Neurol 60:1740–1744
Huang C, Wahlund LO, Almkvist O, Elehu D, Svensson L, Jonsson T, Winblad B, Julin P (2003) Voxel– and VOI-based analysis of SPECT CBF in relation to clinical and psychological heterogeneity of mild cognitive impairment. Neuroimage 19:1137–1144
Padovani A, Pastorino L, Borroni B, Colciaghi F, Rozzini L, Monastero R, Perez J, Pettinati C, Mussi M, Parinello G, Cottini E, Lenzi GL, Trabucchi M, Cattabeni F, Di Luca M (2001) Amyloid Precursor Protein in Platelets: a peripheral marker for the diagnosis of sporadic AD. Neurology 57:2243–2248
Tatsch K, Asenbaum S, Bartenstein P, Catafau A, Haldin C, Pilowsky LS, Pupi A; European Association of Nuclear Medicine (2002) European Association of Nuclear Medicine procedure guidelines for brain perfusion SPET using (99m)Tc–labelled radiopharmaceuticals. Eur J Nucl Mol Imaging 29:BP36–42
Brett M, Anton JL, Valabregue R, Poline JB (2002) Region of interest analysis using an SPM toolbox. NeuroImage 16:abstract N2
Okamura N, Arai H, Maruyama M, Higuchi M, Matsui T, Tanji H, Seki T, Hirai H, Chiba H, Itoh M, Sasaki H (2002) Combined analysis of CSF Tau levels and 123I–Iodoamphetamine SPECT in Mild Cognitive Impairment: implications for a novel predictor of Alzheimer's disease. Am J Psychiatry 159:474–476
Author information
Authors and Affiliations
Corresponding author
Additional information
Drs. Di Luca and Padovani contributed equally to this work.
Rights and permissions
About this article
Cite this article
Borroni, B., Perani, D., Broli, M. et al. Pre–clinical diagnosis of Alzheimer disease combining platelet amyloid precursor protein ratio and rCBF spect analysis. J Neurol 252, 1359–1362 (2005). https://doi.org/10.1007/s00415-005-0867-z
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00415-005-0867-z